Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Vascular endothelial growth factor (VEGF) and mammalian target of rapamycin are well-known therapeutic targets for renal cell carcinoma (RCC). Sunitinib is an agent that targets VEGF receptors and is considered to be a standard treatment for metastatic or unresectable clear cell RCC (ccRCC). However...
Збережено в:
| Автори: | , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Public Library of Science (PLoS)
2015-01-01
|
| Серія: | PLoS ONE |
| Онлайн доступ: | http://europepmc.org/articles/PMC4482605?pdf=render |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|